Mouad Abouqateb

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Thrombotic microangiopathy following CAR T-cell therapy: a case series from the EBMT Complications Working Party.

Thrombotic microangiopathy following CAR T-cell therapy: a case series from the EBMT Complications Working Party.

Journal: Haematologica

Published: June 02, 2026

Total body irradiation versus chemotherapy before stem cell transplantation in children aged two to four with acute lymphoblastic leukemia-an EBMT pediatric diseases working party study.

Total body irradiation versus chemotherapy before stem cell transplantation in children aged two to four with acute lymphoblastic leukemia-an EBMT pediatric diseases working party study.

Journal: Leukemia

Published: April 28, 2026

Single unrelated umbilical cord blood versus unmanipulated haploidentical HCT using PTCy in pediatric AML: a retrospective study on behalf of the EBMT PDWP and CTIWP.

Single unrelated umbilical cord blood versus unmanipulated haploidentical HCT using PTCy in pediatric AML: a retrospective study on behalf of the EBMT PDWP and CTIWP.

Journal: Bone marrow transplantation

Published: June 04, 2025

Accelerated Vascular Aging as a Possible Mechanism of Troponin I Release in the Absence of Clinically Manifested Myocardial Injury.

Accelerated Vascular Aging as a Possible Mechanism of Troponin I Release in the Absence of Clinically Manifested Myocardial Injury.

Journal: Journal of the American Heart Association

Published: March 27, 2025

Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party.

Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party.

Journal: Bone marrow transplantation

Published: March 14, 2025

Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMT.

Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMT.

Journal: Bone marrow transplantation

Published: March 11, 2025

Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working Party.

Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working Party.

Journal: British journal of haematology

Published: March 09, 2025

GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party.

GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party.

Journal: Leukemia

Published: October 01, 2024

Vascular ageing manifestations and hypertension in the community.

Vascular ageing manifestations and hypertension in the community.

Journal: American journal of preventive cardiology

Published: August 17, 2024

Clusters of vascular aging manifestations predict incident cardiovascular events in the community.

Clusters of vascular aging manifestations predict incident cardiovascular events in the community.

Journal: Nature communications

Published: July 09, 2024

How risky is a second allogeneic stem cell transplantation?

How risky is a second allogeneic stem cell transplantation?

Journal: Leukemia

Published: April 10, 2024

ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?

ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?

Journal: Leukemia

Published: January 19, 2024

Showing 1-12 of 14

Last Updated: 09/26/2026